News Ask us!

Fewer side-effects: How we deliver drugs to tumor cells

New technology of Antibody Drug Conjugates (ADCs)

The new technology enables a simple way of connecting the cytsteine residues (SH) of a tumor-sensing antibody (yellow) to toxic drug molecules. The emerging linker is highly stable during blood circulation and enables therefore a safe transport to the tumor side. (Visualisation by Barth van Rossum/FMP)

Treating cancer more selectively and more effectively – this could be achieved with an innovative technology developed by teams of researchers at FMP and the Ludwig-Maximilians-Universität München (LMU). The process transforms proteins and antibodies into stable, highly functional drug transporters, with which tumor cells can be detected and killed.

Christian Hackenberger Group

 


Contact

Portrait

Prof. Dr. Christian Hackenberger

Head Hackenberger Group,

  • Humboldt-Leibniz Professor Chemical Biology Humboldt-Universität zu Berlin

Research Section

Chemical Biology

related news